Cargando…

Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma

BACKGROUND: In early-stage mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, limited skin involvement with patches and plaques is associated with a favorable prognosis. Nevertheless, approximately 20–30% of cases progress to tumors or erythroderma, resulting in poor outcome....

Descripción completa

Detalles Bibliográficos
Autores principales: Rindler, Katharina, Jonak, Constanze, Alkon, Natalia, Thaler, Felix M., Kurz, Harald, Shaw, Lisa E., Stingl, Georg, Weninger, Wolfgang, Halbritter, Florian, Bauer, Wolfgang M., Farlik, Matthias, Brunner, Patrick M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477535/
https://www.ncbi.nlm.nih.gov/pubmed/34583709
http://dx.doi.org/10.1186/s12943-021-01419-2
_version_ 1784575863506862080
author Rindler, Katharina
Jonak, Constanze
Alkon, Natalia
Thaler, Felix M.
Kurz, Harald
Shaw, Lisa E.
Stingl, Georg
Weninger, Wolfgang
Halbritter, Florian
Bauer, Wolfgang M.
Farlik, Matthias
Brunner, Patrick M.
author_facet Rindler, Katharina
Jonak, Constanze
Alkon, Natalia
Thaler, Felix M.
Kurz, Harald
Shaw, Lisa E.
Stingl, Georg
Weninger, Wolfgang
Halbritter, Florian
Bauer, Wolfgang M.
Farlik, Matthias
Brunner, Patrick M.
author_sort Rindler, Katharina
collection PubMed
description BACKGROUND: In early-stage mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, limited skin involvement with patches and plaques is associated with a favorable prognosis. Nevertheless, approximately 20–30% of cases progress to tumors or erythroderma, resulting in poor outcome. At present, factors contributing to this switch from indolent to aggressive disease are only insufficiently understood. METHODS: In patients with advanced-stage MF, we compared patches with longstanding history to newly developed plaques and tumors by using single-cell RNA sequencing, and compared results with early-stage MF as well as nonlesional MF and healthy control skin. RESULTS: Despite considerable inter-individual variability, lesion progression was uniformly associated with downregulation of the tissue residency markers CXCR4 and CD69, the heat shock protein HSPA1A, the tumor suppressors and immunoregulatory mediators ZFP36 and TXNIP, and the interleukin 7 receptor (IL7R) within the malignant clone, but not in benign T cells. This phenomenon was not only found in conventional TCR-αβ MF, but also in a case of TCR-γδ MF, suggesting a common mechanism across MF subtypes. Conversely, malignant cells in clinically unaffected skin from MF patients showed upregulation of these markers. CONCLUSIONS: Our data reveal a specific panel of biomarkers that might be used for monitoring MF disease progression. Altered expression of these genes may underlie the switch in clinical phenotype observed in advanced-stage MF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-021-01419-2.
format Online
Article
Text
id pubmed-8477535
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84775352021-09-29 Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma Rindler, Katharina Jonak, Constanze Alkon, Natalia Thaler, Felix M. Kurz, Harald Shaw, Lisa E. Stingl, Georg Weninger, Wolfgang Halbritter, Florian Bauer, Wolfgang M. Farlik, Matthias Brunner, Patrick M. Mol Cancer Research BACKGROUND: In early-stage mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, limited skin involvement with patches and plaques is associated with a favorable prognosis. Nevertheless, approximately 20–30% of cases progress to tumors or erythroderma, resulting in poor outcome. At present, factors contributing to this switch from indolent to aggressive disease are only insufficiently understood. METHODS: In patients with advanced-stage MF, we compared patches with longstanding history to newly developed plaques and tumors by using single-cell RNA sequencing, and compared results with early-stage MF as well as nonlesional MF and healthy control skin. RESULTS: Despite considerable inter-individual variability, lesion progression was uniformly associated with downregulation of the tissue residency markers CXCR4 and CD69, the heat shock protein HSPA1A, the tumor suppressors and immunoregulatory mediators ZFP36 and TXNIP, and the interleukin 7 receptor (IL7R) within the malignant clone, but not in benign T cells. This phenomenon was not only found in conventional TCR-αβ MF, but also in a case of TCR-γδ MF, suggesting a common mechanism across MF subtypes. Conversely, malignant cells in clinically unaffected skin from MF patients showed upregulation of these markers. CONCLUSIONS: Our data reveal a specific panel of biomarkers that might be used for monitoring MF disease progression. Altered expression of these genes may underlie the switch in clinical phenotype observed in advanced-stage MF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-021-01419-2. BioMed Central 2021-09-28 /pmc/articles/PMC8477535/ /pubmed/34583709 http://dx.doi.org/10.1186/s12943-021-01419-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rindler, Katharina
Jonak, Constanze
Alkon, Natalia
Thaler, Felix M.
Kurz, Harald
Shaw, Lisa E.
Stingl, Georg
Weninger, Wolfgang
Halbritter, Florian
Bauer, Wolfgang M.
Farlik, Matthias
Brunner, Patrick M.
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma
title Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma
title_full Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma
title_fullStr Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma
title_full_unstemmed Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma
title_short Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma
title_sort single-cell rna sequencing reveals markers of disease progression in primary cutaneous t-cell lymphoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477535/
https://www.ncbi.nlm.nih.gov/pubmed/34583709
http://dx.doi.org/10.1186/s12943-021-01419-2
work_keys_str_mv AT rindlerkatharina singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT jonakconstanze singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT alkonnatalia singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT thalerfelixm singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT kurzharald singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT shawlisae singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT stinglgeorg singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT weningerwolfgang singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT halbritterflorian singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT bauerwolfgangm singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT farlikmatthias singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma
AT brunnerpatrickm singlecellrnasequencingrevealsmarkersofdiseaseprogressioninprimarycutaneoustcelllymphoma